Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Head & Neck 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Recurrence 3Neoplasm Metastasis 3Melanoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Cutaneous Squamous Cell Carcinoma 2Carcinoma, Basal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Advanced Non-Small Cell Lung Carcinoma 1Adenocarcinoma 1

Interventions

HhAntag691 14sonidegib 4methyl 5-aminolevulinate 3Photochemotherapy 3Aminolevulinic Acid 3tazarotene 2cemiplimab 2IPI-926 2Drug Evaluation 21-phenyl-3,3-dimethyltriazene 2silmitasertib 1remetinostat 1prednylidene 1pembrolizumab 1deltacortene 1Tacrolimus 1Risk Factors 1Prednisone 1Nivolumab 1NVP-BKM120 1Mohs Surgery 1Mindfulness 1Midazolam 1Itraconazole 1Ipilimumab 1IFL protocol 1Folfox protocol 1Fluorouracil 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Basal Cell × cemiplimab × Clear all
NCT04916002 2025-12-05

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Regeneron Pharmaceuticals

Phase 2 Terminated
77 enrolled 18 charts
BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Regeneron Pharmaceuticals

Phase 2 Completed
138 enrolled 21 charts 1 FDA
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡